|
FY2025
12 months to Dec 31, 2025
|
FY2024
12 months to Dec 31, 2024
|
FY2023
12 months to Dec 31, 2023
|
FY2022
12 months to Dec 31, 2022
|
FY2021
12 months to Dec 31, 2021
|
|
|---|---|---|---|---|---|
| Operating activities | |||||
| Net loss | |||||
| Reconciliation of net loss to net cash used in operating activities: | |||||
| Depreciation and amortization | |||||
| Stock-based compensation expense | |||||
| Other non-cash items, net | |||||
| Acquired in-process research and development | |||||
| Changes in: | |||||
| Accounts receivable | |||||
| Prepaid expenses and other assets | |||||
| Accounts payable and accrued expenses | |||||
| Deferred revenue | |||||
| Operating lease assets and liabilities | |||||
| Other liabilities, net | |||||
| Net cash used in operating activities | |||||
| Investing activities | |||||
| Purchase of property, plant and equipment | |||||
| Purchase of in-process research and development | |||||
| Investment in equity securities | |||||
| Sale of equity securities | |||||
| Purchases of marketable debt securities | |||||
| Maturities of marketable debt securities | |||||
| Net cash used in (provided by) investing activities | |||||
| Financing activities | |||||
| Proceeds from issuance of common shares, net of issuance costs | |||||
| Proceeds from exercise of options and ESPP contributions, net of issuance costs | |||||
| Net cash provided by financing activities | |||||
| Effect of exchange rate changes on cash | |||||
| Increase (decrease) in cash | |||||
| Cash, cash equivalents and restricted cash, beginning of period | |||||
| Cash, cash equivalents and restricted cash, end of period | |||||
| Supplemental disclosure of non-cash investing and financing activities | |||||
| Property and equipment purchases in accounts payable and accrued expenses | |||||
| Equity issuance costs in accounts payable and accrued expenses | |||||
| Acquired in-process research and development expense related to issuance of common shares | |||||
Loading...
